E-viri
PDF
Recenzirano
Odprti dostop
-
Dangas, George D; Tijssen, Jan G.P; Wöhrle, Jochen; Søndergaard, Lars; Gilard, Martine; Möllmann, Helge; Makkar, Raj R; Herrmann, Howard C; Giustino, Gennaro; Baldus, Stephan; De Backer, Ole; Guimarães, Ana H.C; Gullestad, Lars; Kini, Annapoorna; von Lewinski, Dirk; Mack, Michael; Moreno, Raúl; Schäfer, Ulrich; Seeger, Julia; Tchétché, Didier; Thomitzek, Karen; Valgimigli, Marco; Vranckx, Pascal; Welsh, Robert C; Wildgoose, Peter; Volkl, Albert A; Zazula, Ana; van Amsterdam, Ronald G.M; Mehran, Roxana; Windecker, Stephan
The New England journal of medicine, 01/2020, Letnik: 382, Številka: 2Journal Article, Web Resource
Patients who had undergone successful TAVR were randomly assigned to receive either a rivaroxaban-based antithrombotic regimen or an antiplatelet-based antithrombotic regimen. At 17 months, the primary outcome of death or thromboembolic complications occurred more frequently with rivaroxaban.
